Covid-19. Covid-19 disease
Conditions
Interventions
Intervention 1: Test group: treatment with standard regimen along with Montelukast (current drugs for COVID-19 treatment such as Caletra and supportive treatment+ Montelukast at dose 10mg per day for
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: All hospitalized patients with confirmed COVID-19 at both gender and 18-90 ages include in this study All hospitalized patients with confirmed COVID-19 without other severe disease Patient consent
Exclusion criteria
Exclusion criteria: Patients with suspected COVID-19 History of allergy to Montelukast lack of cooperation from the patient
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: During of study (10 days). Method of measurement: Scoring (mild, moderate, sever).;Cough. Timepoint: During of study (10 days). Method of measurement: Scoring (mild, moderate, sever).;Blood oxygen saturation. Timepoint: During of study (10 days). Method of measurement: Percentage of blood oxygen. | — |
Primary
| Measure | Time frame |
|---|---|
| Change of interleukin levels. Timepoint: Beging of study and 10 days later. Method of measurement: With ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Najafzadehvarzi
Babol University of Medical Sciences
Outcome results
None listed